Literature DB >> 22560072

Promising growth and investment in the cell therapy industry during the first quarter of 2012.

David A Brindley1, Natasha L Davie, William A Sahlman, Gregory A Bonfiglio, Emily J Culme-Seymour, Brock C Reeve, Chris Mason.   

Abstract

In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.
Copyright © 2012 Elsevier Inc. All rights reserved.

Mesh：

Year:  2012        PMID： 22560072     DOI： 10.1016/j.stem.2012.04.018

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  3 in total

1.  A microparticle approach for non-viral gene delivery within 3D human mesenchymal stromal cell aggregates.

Authors:  Andrew S Khalil; Xiaohua Yu; Phuong N Dang; Eben Alsberg; William L Murphy
Journal:  Acta Biomater       Date:  2019-04-18       Impact factor: 8.947

2.  An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.

Authors:  David Pettitt; Zeeshaan Arshad; Benjamin Davies; James Smith; Anna French; Doug Cole; Kim Bure; Sue Dopson; David DiGiusto; Jeff Karp; Brock Reeve; Richard Barker; Georg Holländer; David Brindley
Journal:  Syst Rev       Date:  2017-06-26

3.  Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells.

Authors:  Jessica S Elman; Ryan C Murray; Ryan M Murray; Fangjing Wang; Keyue Shen; Shan Gao; Kevin E Conway; Martin L Yarmush; Bakhos A Tannous; Ralph Weissleder; Biju Parekkadan
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.